Ublituximab
Chemical compound From Wikipedia, the free encyclopedia
Ublituximab, sold under the brand name Briumvi, is an immunomodulator used for the treatment of multiple sclerosis.[1][4] It is a CD20-directed cytolytic monoclonal antibody.[1]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | CD20 |
| Clinical data | |
| Trade names | Briumvi |
| Other names | ublituximab-xiiy |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a623008 |
| License data |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6418H9866N1702O2006S48 |
| Molar mass | 144504.31 g·mol−1 |
| (what is this?) (verify) | |
The most common adverse reactions include infusion reactions, including fever, chills, headache, influenza-like illness, elevated heart rate, nausea, throat irritation, reddening of the skin (erythema) and an anaphylactic (allergic) reaction; infections including serious and fatal bacterial, fungal, and new or reactivated viral infections and reduction in immunoglobulins.[4]
It was approved for medical use in the United States in December 2022,[1][5][6][7] and in the European Union in May 2023.[3]
Medical uses
Ublituximab is indicated for the treatment of relapsing-remitting, active secondary progressive, and clinically isolated syndrome forms of multiple sclerosis in adults.[1][4][6]
In the European Union, ublituximab is indicated for the treatment of adults with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.[3]
History
Researchers demonstrated the efficacy of ublituximab in two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in participants with relapsing forms of multiple sclerosis treated for 96 weeks.[4] Participants were randomized to receive either ublituximab or teriflunomide, the active comparator.[4] The primary outcome of both studies was the annualized relapse rate over the treatment period.[4] In both studies, ublituximab significantly lowered the annualized relapse rate compared to teriflunomide.[4]
Society and culture
Names
Ublituximab is the international nonproprietary name (INN).[8]
References
Further reading
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.